A dose titration model for recombinant GH substitution aiming at normal plasma concentrations of IGF-I in hypopituitary adults

Division of Internal Medicine, Department of Medicine and Care, Faculty of Health Sciences, Universitetssjukhuset, S-581 85 Linköping, Sweden.
European Journal of Endocrinology (Impact Factor: 4.07). 08/2002; 147(1):49-57. DOI: 10.1530/eje.0.1470049
Source: PubMed


To evaluate a dose titration model for recombinant human GH substitution in adult patients with GH deficiency, aiming at normal plasma levels of IGF-I.
Eighteen patients participated and a start dose of 0.17 mg GH/day was used except by two men who started with 0.33 mg/day. To demonstrate a clear GH effect the patients were first titrated, with steps of 0.17 mg GH/day every 6-8 weeks, to IGF-I levels in the upper range of age-adjusted reference values. The GH dose was then reduced 1 dose step and kept for a further 6 months. For comparison we investigated 17 healthy control subjects.
Plasma IGF-I was increased after 2 weeks on the start dose and did not increase further for up to 8 weeks. Women had significantly lower GH sensitivity than men measured as net increment of IGF-I on the start dose of GH. GH sensitivity was not changed by age. The plasma IGF-I levels increased from 76.3+/-47.0 (s.d.) to 237+/-97 microg/l at the end of the study (P<0.001), and similar IGF-I levels were obtained in both sexes. The maintenance median GH dose was 0.33 mg/day in males and 0.83 mg/day in females (P=0.017). The GH dose correlated negatively with age in both sexes. Body weight, very low density triglycerides, lipoprotein(a) (Lp(a)), and fasting insulin increased, whereas insulin sensitivity index (QUICKI) decreased significantly. In comparison with the controls, the patients had lower fasting blood glucose, fasting insulin and Lp(a) levels at baseline, but these differences disappeared after GH substitution. The two groups had equal insulin sensitivity (QUICKI), but 2 h oral glucose tolerance test values of blood glucose and insulin were significantly higher in the patients at the end of the study.
In conclusion our data suggest that the starting dose of GH substitution and the dose titration steps should be individualised according to GH sensitivity (gender) and the IGF-I level aimed for (age). The reduced insulin sensitivity induced by GH substitution could be viewed as a normalisation if compared with control subjects.

Download full-text


Available from: Bertil Ekman,
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: IGF-I circulates bound to specific IGF binding proteins (IGFBP-1 to -6) in plasma, of which IGFBP-3 binds the majority of IGF-I. In children, IGF-I and IGFBP-3 are primarily regulated by the pulsatile GH secretion, but other factors like sex steroids, nutritional status, liver and renal function may influence serum levels. In adults, GH secretion stimulate IGF-I and IGFBP-3 but plays a minor role in the regulation compared to children. IGF-I and IGFBP-3 exhibit little diurnal fluctuations and vary little according to menstrual stage. By contrast, age, puberty, gender and body composition influence serum levels markedly, and has to be taken into account before an individual value can be evaluated. In children with central precocious puberty IGF-I and IGFBP-3 are increased compared to prepubertal levels, and decrease during GnRH agonist therapy. IGF-I levels decline with increasing age in adults. Similarly, IGFBP-3 decrease although less markedly compared to IGF-I. This may result in decreasing levels of free (biologically active) IGF-I which has been suggested to be related to the process of ageing. In line with this suggestion, prospective studies of healthy adults have found that IGF-I levels in the upper part of the normal range is associated with increased risk of future development of prostate, breast and colorectal cancer. Conversely, IGF-I levels in the lower part of the normal range is associated with increased risk of future osteoporosis, impaired glucose tolerance and ischemic heart disease. IGF-I and IGFBP-3 levels are subnormal in children with GH deficiency, as well as in adults with GHD of childhood onset. In patients with GHD acquired in adulthood IGF-I and IGFBP-3 levels are generally low, but cannot be used as single diagnostic parameters. GH replacement therapy increases IGF-I and IGFBP-3 into the normal range, and current international guidelines suggest doses to be titrated according to IGF-I levels. Furthermore, IGF-I and IGFBP-3 levels are supranormal in patients with active acromegaly. Normalization of IGF-I and IGFBP-3 is considered one of the criteria for succesful treatment. Thus, in patients with GH secretory disorders (deficiency or excess) assessment of IGF-I and IGFBP-3 serum concentrations adjusted according to age and gender may ensure correct diagnosis and monitoring of treatment efficiency.
    Growth Hormone & IGF Research 09/2003; 13(4):113-70. DOI:10.1016/S1096-6374(03)00038-8 · 1.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the present report, we have compared 12 months of rhGH therapy given daily (D) at the beginning and then on alternate days (A) to 20 subjects with severe adult-onset GH deficiency (GHD). Aim of the study was to establish whether the lower frequency injection regimen is as effective as the daily dose. Measurements included: IGF-I levels, body composition (BF%), lipid profile, insulin sensitivity by homeostasis model assessment (HOMA-IR) and quantitative insulin check index (QUICKI), as well as thyroid function. Evaluation on A therapy was performed both 12 and 36 hours after the last rhGH injection. The final rhGH dose was 0.3 +/- 0.1mg/day. During A, the dose used in D was doubled and given on alternate days. Recombinant hGH given during the A period induced changes in IGF-I levels, BF% and lipid profile comparable to daily treatment. HOMA-IR increased similarly after both regimens, though QUICKI did not significantly change. A significant reduction in serum FT4 levels occurred after both D and A therapy, so that an adjustment of L-T4 replacement dose in 5 of 20 patients was necessary. No differences were found in the various parameters after 12 and 36 hours post rhGH injection. In conclusion, rhGH therapy given on alternate days is clinically effective and may result in improved patient compliance. Monitoring glucose tolerance and thyroid function while on rhGH is essential.
    Hormone and Metabolic Research 10/2003; 35(9):557-61. DOI:10.1055/s-2003-42659 · 2.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We studied the effects of individualised growth hormone (GH) substitution, aiming at normal insulin-like growth factor I (IGF-I) levels, on biomechanical output and surface electromyogram (EMG) of isokinetic muscle strength and endurance performance in 18 hypopituitary adults and compared with 17 matched healthy controls. The muscle function tests consisted of isokinetic contractions of the right knee extensors, from which torque and EMG were recorded. Three patients were excluded from the final analysis of the muscle function tests due to technical errors and one control subject moved from the area during the study. We found that GH-deficient adults without GH substitution were weaker and had less endurance than healthy control subjects. At the group level, plasma levels of IGF-I were normalised but generally no significant effects upon biomechanical output and EMG were found after dose titration and 6 months of a constant GH dose. However, subjects with the largest changes in IGF-I had significantly better biomechanical output and EMG compared to those with small changes in IGF-I. This finding may indicate that the net increase in IGF-I levels is critical for improvements in biomechanical output, EMG and perception of fatigue to occur.
    Arbeitsphysiologie 12/2003; 90(5-6):496-504. DOI:10.1007/s00421-003-0895-2 · 2.19 Impact Factor
Show more